South Korea
· Delayed Price · Currency is KRW SAMSUNG PHARM. Co., LTD. Statistics
Total Valuation
SAMSUNG PHARM. Co., LTD. has a market cap or net worth of KRW 142.50 billion.
| Market Cap | 142.50B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SAMSUNG PHARM. Co., LTD. has 94.12 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 94.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -6.93% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 4.63% |
| Float | 84.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.98 |
| PB Ratio | 0.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.38 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.97 |
| Interest Coverage | -11.20 |
Financial Efficiency
Return on equity (ROE) is -4.40% and return on invested capital (ROIC) is -3.60%.
| Return on Equity (ROE) | -4.40% |
| Return on Assets (ROA) | -3.34% |
| Return on Capital (ROIC) | -3.60% |
| Revenue Per Employee | 186.06M |
| Profits Per Employee | -24.83M |
| Employee Count | 240 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 2.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.84% in the last 52 weeks. The beta is 0.93, so SAMSUNG PHARM. Co., LTD.'s price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -41.84% |
| 50-Day Moving Average | 1,667.28 |
| 200-Day Moving Average | 1,721.05 |
| Relative Strength Index (RSI) | 37.11 |
| Average Volume (20 Days) | 452,265 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SAMSUNG PHARM. Co., LTD. had revenue of KRW 44.65 billion and -5.96 billion in losses. Loss per share was -101.96.
| Revenue | 44.65B |
| Gross Profit | 8.02B |
| Operating Income | -8.77B |
| Pretax Income | -5.90B |
| Net Income | -5.96B |
| EBITDA | -4.67B |
| EBIT | -8.77B |
| Loss Per Share | -101.96 |
Balance Sheet
The company has 11.22 billion in cash and 14.28 billion in debt, giving a net cash position of -3.06 billion or -32.53 per share.
| Cash & Cash Equivalents | 11.22B |
| Total Debt | 14.28B |
| Net Cash | -3.06B |
| Net Cash Per Share | -32.53 |
| Equity (Book Value) | 134.01B |
| Book Value Per Share | 2,288.01 |
| Working Capital | 30.30B |
Cash Flow
In the last 12 months, operating cash flow was -6.42 billion and capital expenditures -8.31 billion, giving a free cash flow of -14.73 billion.
| Operating Cash Flow | -6.42B |
| Capital Expenditures | -8.31B |
| Free Cash Flow | -14.73B |
| FCF Per Share | -156.47 |
Margins
Gross margin is 17.96%, with operating and profit margins of -19.63% and -13.34%.
| Gross Margin | 17.96% |
| Operating Margin | -19.63% |
| Pretax Margin | -13.21% |
| Profit Margin | -13.34% |
| EBITDA Margin | -10.47% |
| EBIT Margin | -19.63% |
| FCF Margin | -32.98% |
Dividends & Yields
SAMSUNG PHARM. Co., LTD. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.91% |
| Shareholder Yield | -24.91% |
| Earnings Yield | -6.73% |
| FCF Yield | -10.33% |
Stock Splits
The last stock split was on April 26, 1995. It was a forward split with a ratio of 1.1.
| Last Split Date | Apr 26, 1995 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
SAMSUNG PHARM. Co., LTD. has an Altman Z-Score of 4.08.
| Altman Z-Score | 4.08 |
| Piotroski F-Score | n/a |